Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 12, 2026, 11:12 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2065–2088 of 5,326 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Continuous Dose Clear all

Conditions: Primary Fibromyalgia
Interventions: GRT9906, Placebo; Drug
Lead sponsor: Grünenthal GmbH; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 6
States / cities: DeLand, Florida • Charlotte, North Carolina • Medford, Oregon + 2 more

Conditions: Statin Adverse Reaction
Interventions: Statins, Placebo; Drug
Lead sponsor: Rockefeller University; Other
Eligibility: 40 Years to 60 Years
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 1
States / cities: New York, New York

Conditions: Hypertension, Pulmonary
Interventions: Tadalafil, Placebo, ERA as specific PAH treatment; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 6 Months to 17 Years
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2021
U.S. locations: 7
States / cities: Atlanta, Georgia • Detroit, Michigan • Cincinnati, Ohio + 4 more

Conditions: Adult Acute Myeloid Leukemia, Secondary Acute Myeloid Leukemia, Therapy-Related Acute Myeloid Leukemia
Interventions: Cytarabine, Decitabine, Idarubicin, Laboratory Biomarker Analysis, Liposome-encapsulated Daunorubicin-Cytarabine, Quality-of-Life Assessment, Questionnaire Administration, Azacitidine, Venetoclax, glasdegib; Drug · Other
Lead sponsor: University of Nebraska; Other
Eligibility: 60 Years and older
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2024
U.S. locations: 1
States / cities: Omaha, Nebraska

Conditions: Acne Vulgaris
Interventions: Doxycycline 100mg, Aczone 5% gel; Drug
Lead sponsor: Derm Research, PLLC; Other
Eligibility: 12 Years to 85 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Louisville, Kentucky

Conditions: Insomnia, Insomnia Chronic
Interventions: Zolpidem tartrate; Drug
Lead sponsor: University of Pennsylvania; Other
Eligibility: 40 Years to 85 Years
Enrollment: 197 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Recurrent Mycosis Fungoides, Refractory Mycosis Fungoides, Stage I Mycosis Fungoides, Stage II Mycosis Fungoides, Stage III Mycosis Fungoides
Interventions: Quality-of-Life Assessment, Objective Grading of Skin Findings; Other
Lead sponsor: Vanderbilt-Ingram Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2030
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Atopic Dermatitis
Interventions: lebrikizumab; Drug
Lead sponsor: Johann E Gudjonsson MD PhD; Other
Eligibility: 18 Years and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 2
States / cities: Folsom, California • Ann Arbor, Michigan

Conditions: Solid Tumors, Breast Cancer, Neoplasms
Interventions: SU011248; Capecitabine; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 77 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 3
States / cities: Indianapolis, Indiana • Albuqurque, New Mexico • Nashville, Tennessee

Conditions: Pediatric Obesity
Interventions: Phentermine/Topiramate (Qsymia), Placebo; Drug
Lead sponsor: University of Minnesota; Other
Eligibility: 12 Years to 20 Years
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Brain Tumors, Central Nervous System Tumors
Interventions: carboplatin, lomustine, procarbazine hydrochloride, thioguanine, vincristine sulfate; Drug
Lead sponsor: Children's Oncology Group; Network
Eligibility: Up to 9 Years
Enrollment: 428 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1997 – 2012
U.S. locations: 179
States / cities: Mobile, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 141 more

Conditions: Bipolar Disorder
Interventions: Quetiapine; Drug
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Opioid-use Disorder
Interventions: Buprenorphine, Naltrexone, Vivitrol; Drug
Lead sponsor: New York State Psychiatric Institute; Other
Eligibility: 18 Years to 60 Years
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: New York, New York

Conditions: Prostate Cancer
Interventions: Degarelix, Goserelin acetate; Drug
Lead sponsor: Ferring Pharmaceuticals; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 288 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 8
States / cities: Aurora, Colorado • Denver, Colorado • Dover, Delaware + 5 more

Conditions: Leiomyosarcoma
Interventions: Unesbulin, Dacarbazine, Placebo; Drug · Other
Lead sponsor: PTC Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 359 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 23
States / cities: Duarte, California • Los Angeles, California • Santa Monica, California + 18 more

Conditions: Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer, Advanced Solid Tumor With Evidence of Germline or Somatic BRCA
Interventions: Rucaparib; Drug
Lead sponsor: pharmaand GmbH; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 136 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2019
U.S. locations: 6
States / cities: San Francisco, California • Sarasota, Florida • Boston, Massachusetts + 3 more

Conditions: Lymphoma, Non-Hodgkin
Interventions: TAK-659, Bendamustine, Rituximab, Gemcitabine, Lenalidomide, Ibrutinib; Drug
Lead sponsor: Millennium Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 11
States / cities: Tucson, Arizona • La Jolla, California • West Hollywood, California + 8 more

Conditions: Neuroendocrine Tumors
Interventions: 177Lu-edotreotide PRRT, Everolimus, Amino-Acid Solution; Drug · Other
Lead sponsor: ITM Solucin GmbH; Industry
Eligibility: 18 Years and older
Enrollment: 324 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2029
U.S. locations: 6
States / cities: Gilbert, Arizona • Stanford, California • Tampa, Florida + 3 more

Conditions: Pancreatic Ductal Adenocarcinoma (PDAC), Cancer of Pancreas, Pancreatic Cancer, Adult, Pancreas Adenocarcinoma, Pancreatic Neoplasms, Pancreatic Cancer Non-resectable, Pancreatic Cancer Resectable
Interventions: Oxaliplatin, Leucovorin, Irinotecan Hydrochloride, 5-FU; Drug
Lead sponsor: UNC Lineberger Comprehensive Cancer Center; Other
Eligibility: 18 Years to 99 Years
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2030
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Tethered Spinal Cord, Brain Tumor, Cranio Cervical Compression
Interventions: Isoflurane, Propofol, Dexmedetomidine; Other
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 2 Years to 12 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2018
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Non-Transfusion-dependent Alpha-Thalassemia, Non-Transfusion-dependent Beta-Thalassemia
Interventions: Mitapivat, Placebo Matching Mitapivat; Drug
Lead sponsor: Agios Pharmaceuticals, Inc.; Industry
Eligibility: 1 Year to 17 Years
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2032
U.S. locations: 5
States / cities: Palo Alto, California • Atlanta, Georgia • New York, New York + 2 more

Conditions: Advanced Cancer, Metastatic Cancer, Malignant Neoplastic Disease
Interventions: MRTX849, Pembrolizumab, Cetuximab, Afatinib; Drug
Lead sponsor: Mirati Therapeutics Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 731 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 221
States / cities: Birmingham, Alabama • Anchorage, Alaska • Phoenix, Arizona + 156 more

Conditions: Apnea of Prematurity
Interventions: Caffeine, Sterile Water Placebo; Drug · Other
Lead sponsor: University of California, Irvine; Other
Eligibility: 1 Week to 40 Weeks
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Orange, California

Conditions: Recurrent Head and Neck Cancer, Metastatic Head and Neck Cancer
Interventions: docetaxel, placebo, gefitinib; Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 270 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2012
U.S. locations: 1
States / cities: Boston, Massachusetts

Search by objective public record fields.

Efficacy and Safety of GRT9906 Tablets Compared to Placebo in Patients With Fibromyalgia

Quality of Life in Patients With Statin-Associated Myopathy

A Study of Tadalafil in Pediatric Participants With Pulmonary Arterial Hypertension (PAH)

Geriatric Assessment & Genetic Profiling to Personalize Therapy in Older Adults With Acute Myeloid Leukemia

Aczone 5% Gel as Maintenance Treatment of Acne Vulgaris Following Completion of Oral Doxycycline and Aczone 5% Gel

Partial Reinforcement II: Three Approaches to Maintenance Therapy for Chronic Insomnia

Low-Dose Total Skin Electron Therapy in Treating Patients With Refractory or Relapsed Stage IB-IIIA Mycosis Fungoides

Lebrikizumab in Moderate-to-severe Atopic Dermatitis

A Study To Find The Best Doses Of SU011248 (Sunitinib) And Capecitabine When These Drugs Are Administered Together

Phentermine/Topiramate in Adolescents With Type 2 Diabetes and Obesity

Combination Chemotherapy in Treating Children With Progressive Brain Tumors

Pharmacokinetics of Quetiapine Across Pregnancy and Postpartum

Buprenorphine as Adjunct to Outpatient Induction Onto Vivitrol

A Degarelix Trial in Patients With Prostate Cancer

A Study of Unesbulin in Participants With Advanced Leiomyosarcoma (LMS)

A Study of Oral Rucaparib in Patients With a Solid Tumor (Phase I) or With gBRCA Mutation Ovarian Cancer (Phase II)

A Study of TAK-659 in Combination With Bendamustine (+/-Rituximab), Gemcitabine, Lenalidomide, or Ibrutinib for the Treatment of Participants With Advanced Non-Hodgkin Lymphoma

Efficacy and Safety of 177Lu-edotreotide PRRT in GEP-NET Patients

Tumor Subtypes in Subjects on FOLFIRINOX With Non-Metastatic Pancreatic Cancer

Dexmedetomidine on Intraoperative Somatosensory and Motor Evoked Potential Monitoring During Neurosurgery in Pediatric Patients

A Study to Investigate the Efficacy, Pharmacokinetics, and Safety of Mitapivat in Pediatric Participants With α- or β-Non-Transfusion-Dependent Thalassemia

Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1

Caffeine Use in the Management of Preterm Infants

Phase III Trial Of Docetaxel Versus Docetaxel Plus ZD1839 In Head And Neck Cancer